염증 관련 바이오마커 시장 : 전략적 인사이트와 예측(2026-2035년)

The Inflammation-related Biomarkers Market is anticipated to grow at a CAGR of 10.7% from USD 7.44 billion in 2026 to USD 18.51 billion in 2035.

The inflammation-related biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the growing recognition that chronic inflammation underlies numerous disease states. The market's evolution is characterized by the increasing demand for objective biological indicators capable of supporting diagnosis, prognosis, and treatment monitoring across diverse therapeutic areas, including autoimmune diseases, oncology, cardiovascular diseases, and infectious diseases. The convergence of advanced analytical platforms, including multiplex biomarker platforms, next-generation sequencing, and mass spectrometry, is enabling more comprehensive characterization of complex inflammatory pathways. Healthcare providers are seeking objective tools to evaluate disease activity and treatment effectiveness as the prevalence of autoimmune and chronic inflammatory diseases continues to rise. Pharmaceutical companies are increasing biomarker integration because therapeutic development requires measurable indicators of biological response. Regulatory agencies increasingly recognize inflammation-related biomarkers as critical tools supporting disease diagnosis, therapeutic development, and precision medicine strategies. The market is witnessing significant investment in multi-omics approaches, cytokine profiling, and AI-enabled biomarker discovery, positioning inflammation-related biomarkers as a core component of precision healthcare across global medical practice.

Market Drivers

• The growing burden of autoimmune and chronic inflammatory diseases represents the primary driver for the inflammation-related biomarkers market. Autoimmune and chronic inflammatory diseases represent major healthcare challenges because persistent inflammation contributes to disease progression and long-term complications. Demand for inflammation-related biomarkers is increasing as healthcare providers seek objective methods for evaluating disease activity and treatment effectiveness. This requirement creates pressure on diagnostics developers to improve biomarker sensitivity and clinical relevance. Industry participants are expanding biomarker development programs to address evolving clinical needs. The outcome is stronger adoption of inflammatory biomarker testing across healthcare systems, resulting in sustained growth in inflammation-related biomarker utilization. The expansion of precision medicine and targeted therapies is further accelerating market growth through demand for biological characterization. Precision medicine relies on biological indicators that support individualized treatment decisions. Demand for inflammation biomarkers is rising because healthcare providers increasingly require patient-specific information regarding immune activity and therapeutic responsiveness. This trend exposes limitations associated with generalized treatment approaches that fail to account for biological variability. Organizations are strengthening biomarker research and validation efforts to improve personalized healthcare delivery. The result is broader integration of biomarker-guided treatment strategies. The increasing use of biomarkers in drug development is driving expansion of biomarker utilization across pharmaceutical research. Drug development depends on measurable biological endpoints that demonstrate treatment effectiveness and mechanism engagement. Demand for inflammation-related biomarkers is increasing as pharmaceutical companies seek earlier indicators of therapeutic response and patient stratification. This challenge increases the importance of biomarkers that support clinical trial efficiency and regulatory submissions. Organizations are incorporating inflammatory biomarkers into development programs to improve decision-making throughout the drug lifecycle. Advancements in multiplex and multi-omics technologies are accelerating market development through scientific advancement. Modern biomarker discovery requires technologies capable of evaluating complex biological interactions. Demand for advanced analytical platforms is increasing because inflammatory pathways involve multiple interconnected cellular and molecular mechanisms.

Market Restraints

• Biomarker validation remains challenging because inflammatory responses vary significantly across patients, diseases, and clinical settings. The biological variability of inflammation creates challenges for consistent biomarker interpretation. Standardization limitations persist because testing methodologies and analytical platforms differ across laboratories and healthcare systems. The lack of harmonized protocols reduces comparability and clinical confidence. High implementation costs associated with advanced molecular and multiplex technologies continue limiting adoption in resource-constrained settings. The significant financial investment required for advanced platforms creates barriers for smaller facilities. Data integration and interpretation challenges create additional complexity for multi-parameter biomarker analysis.

Technology and Biomarker Type Insights

• The technology landscape is characterized by the growing importance of multiplex biomarker platforms and integrated multi-omics approaches. Demand for multiplex biomarker platforms is increasing because inflammatory diseases involve numerous interconnected biological mediators that cannot be adequately characterized through single-marker approaches. This complexity strengthens the role of immunoassays, flow cytometry, PCR, and NGS technologies capable of generating multidimensional biological insights. Immunoassays remain essential for targeted protein biomarker measurement. Mass spectrometry is gaining adoption for comprehensive proteomic profiling. The segment analysis reveals that demand is shifting toward cytokine and chemokine biomarkers because immune-mediated diseases increasingly require dynamic evaluation of inflammatory signaling pathways. Acute phase protein biomarkers, including CRP, continue supporting routine clinical assessment of inflammation. Cellular inflammatory biomarkers provide insight into immune cell involvement. Genetic and genomic inflammatory biomarkers are expanding for patient stratification and precision medicine. Multi-biomarker panels are gaining adoption because inflammatory pathways involve multiple interconnected biological signals. Autoimmune diseases represent a major application because treatment decisions increasingly depend on biological characterization of immune activity. Oncology, cardiovascular diseases, infectious diseases, neurological disorders, and metabolic disorders represent significant and growing application areas. Hospitals and clinical laboratories represent the leading end-user segment, with pharmaceutical and biotechnology companies expanding biomarker utilization. The integration of AI is becoming increasingly important because inflammatory biomarker research generates complex datasets requiring advanced analytical capabilities. Organizations are incorporating machine learning technologies to improve biomarker discovery and clinical interpretation.

Competitive and Strategic Outlook

• The competitive landscape features established life science and diagnostics companies alongside specialized biomarker, analytics, and precision medicine providers. Thermo Fisher Scientific maintains a leading position because its broad portfolio of analytical instruments, immunoassays, molecular biology tools, and translational research solutions supports the entire biomarker development workflow, expanding integrated research and diagnostics capabilities to address growing complexity in biomarker discovery and validation. Roche differentiates itself through the combination of pharmaceutical development, companion diagnostics, and precision medicine initiatives, expanding biomarker-enabled healthcare programs across immunology, oncology, and chronic disease management applications. Danaher occupies a significant position because its operating companies provide technologies that support biomarker discovery, molecular analysis, and translational research, strengthening innovation through continued investment in diagnostics and life sciences capabilities. Bio-Rad remains an important participant because its technologies support assay development, biomarker quantification, and translational research activities, expanding analytical capabilities through continuous technology enhancement and workflow optimization initiatives. QIAGEN maintains strategic importance because molecular diagnostics and sample analysis technologies continue supporting biomarker-driven healthcare approaches, expanding molecular analysis capabilities to address growing requirements within precision medicine and translational research. Agilent supports the market through analytical technologies that enable biomarker characterization and metabolomic, proteomic, and genomic investigations, strengthening innovation efforts to improve analytical performance and research efficiency. Illumina differentiates itself through leadership in sequencing technologies that support genomic and transcriptomic biomarker discovery. Companies are pursuing product portfolio expansion through innovation in multiplex biomarker panels, multi-omics platforms, and AI-enabled discovery tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for biomarker discovery and validation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The inflammation-related biomarkers market is positioned for sustained growth driven by the convergence of chronic disease burden, precision medicine, and technological innovation. The transition from isolated biomarker measurements toward integrated multi-omics and multiplex platforms represents a fundamental shift in precision healthcare. While challenges related to biomarker validation, standardization, and implementation costs persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with inflammation-related biomarkers evolving from a research-centered field into a core component of precision healthcare, supporting diagnosis, treatment optimization, and therapeutic development across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Inflammation-related Biomarkers Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden and Unmet Clinical Needs
• 3.8 Epidemiology and Prevalence Analysis of Inflammation-Associated Disorders
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Testing Volume Analysis
• 3.11 Biomarker Utilization Across Clinical and Research Applications
• 3.12 Inflammation Biomarker Role in Precision Medicine

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Discovery Technologies
• 6.2 Product Innovation and Assay Development
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Multi-omics Integration in Biomarker Research
• 6.6 AI-Enabled Biomarker Identification and Validation
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Inflammation-related Biomarkers Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Technology Platform
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology

9. Inflammation-related Biomarkers Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Cytokine Biomarkers
  • 9.1.2 Chemokine Biomarkers
  • 9.1.3 Acute Phase Protein Biomarkers
  • 9.1.4 Cellular Inflammatory Biomarkers
  • 9.1.5 Genetic and Genomic Inflammatory Biomarkers
  • 9.1.6 Multi-biomarker Panels
• 9.2 By Technology Platform
  • 9.2.1 Immunoassays
  • 9.2.2 Flow Cytometry
  • 9.2.3 Polymerase Chain Reaction (PCR)
  • 9.2.4 Next-Generation Sequencing (NGS)
  • 9.2.5 Mass Spectrometry
  • 9.2.6 Multiplex Biomarker Platforms
• 9.3 By Clinical Application
  • 9.3.1 Autoimmune Diseases
  • 9.3.2 Oncology
  • 9.3.3 Cardiovascular Diseases
  • 9.3.4 Infectious Diseases
  • 9.3.5 Neurological Disorders
  • 9.3.6 Metabolic Disorders
• 9.4 By End User
  • 9.4.1 Hospitals and Clinical Laboratories
  • 9.4.2 Academic and Research Institutes
  • 9.4.3 Pharmaceutical and Biotechnology Companies
  • 9.4.4 Contract Research Organizations

10. Inflammation-related Biomarkers Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Inflammation-related Biomarkers Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 India
• 11.12 South Korea
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Thermo Fisher Scientific Inc.
• 13.2 F. Hoffmann-La Roche Ltd
• 13.3 Danaher Corporation
• 13.4 Bio-Rad Laboratories, Inc.
• 13.5 QIAGEN N.V.
• 13.6 Agilent Technologies, Inc.
• 13.7 Revvity, Inc.
• 13.8 Illumina, Inc.
• 13.9 Standard BioTools Inc.
• 13.10 Olink Holding AB
• 13.11 Bio-Techne Corporation
• 13.12 Becton, Dickinson and Company
• 13.13 Siemens Healthineers AG
• 13.14 NeoGenomics, Inc.
• 13.15 Myriad Genetics, Inc.

14. Inflammation-related Biomarkers Market Commercial Forecast Analysis

• 14.1 Cytokine Biomarker Assays
• 14.2 Multiplex Inflammatory Biomarker Panels
• 14.3 C-Reactive Protein (CRP)-Based Testing Solutions
• 14.4 Interleukin Biomarker Testing Solutions
• 14.5 TNF-Associated Biomarker Testing Solutions
• 14.6 Genomic Inflammation Biomarker Platforms
• 14.7 Proteomic Inflammation Biomarker Platforms

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends
• 16.3 Evolution of Precision Immunology and Biomarker-Guided Care
• 16.4 Future Adoption of Multi-omics and AI-Driven Biomarker Platforms
• 16.5 Long-Term Market Outlook and Strategic Implications